Sunil Narula

760 total citations
9 papers, 41 citations indexed

About

Sunil Narula is a scholar working on Oncology, Hematology and Cancer Research. According to data from OpenAlex, Sunil Narula has authored 9 papers receiving a total of 41 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 4 papers in Hematology and 4 papers in Cancer Research. Recurrent topics in Sunil Narula's work include Multiple Myeloma Research and Treatments (4 papers), Cancer Genomics and Diagnostics (4 papers) and Gastric Cancer Management and Outcomes (2 papers). Sunil Narula is often cited by papers focused on Multiple Myeloma Research and Treatments (4 papers), Cancer Genomics and Diagnostics (4 papers) and Gastric Cancer Management and Outcomes (2 papers). Sunil Narula collaborates with scholars based in United States. Sunil Narula's co-authors include Theodore Karrison, Samantha Lomnicki, Murtuza Rampurwala, Sandeep Gurbuxani, Larry D. Anderson, Daniel V.T. Catenacci, Jagoda Jasielec, Blasé N. Polite, Ankit Kansagra and Andrzej Jakubowiak and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JAMA Oncology.

In The Last Decade

Sunil Narula

7 papers receiving 40 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sunil Narula United States	4	21	21	19	10	4	9	41
Rashmi Khanal United States	4	23 1.1×	8 0.4×	16 0.8×	12 1.2×	5 1.3×	15	42
Vesna Pavasovic United Kingdom	4	12 0.6×	14 0.7×	23 1.2×	14 1.4×	2 0.5×	8	49
Margarita Askelson United States	5	19 0.9×	12 0.6×	14 0.7×	15 1.5×	6 1.5×	16	47
Marianna Dávid Hungary	3	6 0.3×	16 0.8×	12 0.6×	6 0.6×	5 1.3×	7	31
H. Lindemann Germany	5	45 2.1×	12 0.6×	14 0.7×	7 0.7×	18 4.5×	7	59
Cristina Nevado García Spain	3	16 0.8×	25 1.2×	21 1.1×	7 0.7×	6 1.5×	8	35
Richard J. Bellin United States	2	22 1.0×	24 1.1×	48 2.5×	5 0.5×	2 0.5×	3	61
Emiel van der Kouwe Austria	2	7 0.3×	20 1.0×	22 1.2×	6 0.6×	2 0.5×	2	37
Omkar Marathe United States	3	28 1.3×	5 0.2×	15 0.8×	6 0.6×	2 0.5×	12	41
Tracey McCulloch Switzerland	4	19 0.9×	8 0.4×	11 0.6×	22 2.2×	3 0.8×	9	39

Countries citing papers authored by Sunil Narula

Since Specialization

Citations

This map shows the geographic impact of Sunil Narula's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sunil Narula with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sunil Narula more than expected).

Fields of papers citing papers by Sunil Narula

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sunil Narula. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sunil Narula. The network helps show where Sunil Narula may publish in the future.

Co-authorship network of co-authors of Sunil Narula

This figure shows the co-authorship network connecting the top 25 collaborators of Sunil Narula. A scholar is included among the top collaborators of Sunil Narula based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sunil Narula. Sunil Narula is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Cahill, Kirk E., James Godfrey, Chadi Nabhan, et al.. (2025). A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL. Blood Advances. 9(21). 5665–5675.

Kubicki, Tadeusz, Heidi Simmons, Aimaz Afrough, et al.. (2023). Early Peripheral Blood Minimal Residual Disease Status By NGS in Patients with Newly Diagnosed Multiple Myeloma (MM) on a Phase 2 Trial Receiving Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd). Blood. 142(Supplement 1). 1982–1982. 2 indexed citations

Derman, Benjamin A., Ankit Kansagra, Jeffrey A. Zonder, et al.. (2022). Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent. JAMA Oncology. 8(9). 1278–1278. 17 indexed citations

Derman, Benjamin A., Jeffrey A. Zonder, Ankit Kansagra, et al.. (2021). Interim analysis of a phase 2 minimal residual disease (MRD)-adaptive trial of elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd) for newly diagnosed multiple myeloma (MM).. Journal of Clinical Oncology. 39(15_suppl). 8011–8011. 3 indexed citations

Catenacci, Daniel V.T., Bryan Peterson, Leah M. Chase, et al.. (2020). Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): Secondary and final primary efficacy analyses.. Journal of Clinical Oncology. 38(15_suppl). 4561–4561. 2 indexed citations

Catenacci, Daniel V.T., Samantha Lomnicki, Leah M. Chase, et al.. (2020). Personalized ANtibodies for GastroEsophageal Adenocarcinoma (PANGEA): Primary efficacy analysis of the phase II platform trial (NCT02213289).. Journal of Clinical Oncology. 38(4_suppl). 356–356. 5 indexed citations

Catenacci, Daniel V.T., Leah M. Chase, Samantha Lomnicki, et al.. (2019). Perioperative (P) UGT1A1 genotype guided irinotecan (iri) dosing ‘gFOLFIRINOX’ for gastroesophageal adenocarcinoma (GEA).. Journal of Clinical Oncology. 37(15_suppl). 4050–4050.

Joshi, Smita S., Steven B. Maron, Samantha Lomnicki, et al.. (2018). Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): A phase II precision medicine trial (NCT02213289).. Journal of Clinical Oncology. 36(4_suppl). TPS198–TPS198. 9 indexed citations

Narula, Sunil. (2004). Psychological operations (PSYOPs): A conceptual overview. Strategic Analysis. 28(1). 177–192. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact